Navigation Links
Hologic Announces First Quarter Fiscal 2013 Operating Results
Date:2/4/2013

is represents an expected increase of 35% to 36% over second quarter fiscal 2012 revenues of $471.2 million. The increase is driven primarily by the inclusion of revenues related to the Gen-Probe acquisition, the continued ramp-up of new products including the Dimensions, PANTHER, and MyoSure systems and an expected overall improvement in each of the Company's operating segments, partially offset by an elimination in Adiana system revenues and revenues associated with LIFECODES which is expected to be sold during the quarter.
  • The Company expects non-GAAP adjusted EPS of $0.33 to $0.34. This reflects the expected benefit of approximately $0.01 from the recently-reinstated federal research tax credit, offset by the expected impact of the medical device excise tax which is expected to be $0.02 dilutive.
  • Fiscal 2013 (Year Ending September 28, 2013):

  • The Company is reaffirming expected fiscal 2013 non-GAAP adjusted revenues of $2.61 billion to $2.64 billion. Year-over-year this represents an expected increase of 30% to 31% over fiscal 2012 non-GAAP revenues of $2.01 billion. This increase is driven primarily by revenues related to the Gen-Probe acquisition and, to a lesser extent, increases in the Breast Health, GYN Surgical and legacy Diagnostics segments, partially offset by a reduction in Adiana system revenues.
  • The Company expects non-GAAP adjusted EPS of $1.58 to $1.60. This is $0.02 higher than the guidance provided on November 12, 2012 due to the recently-reinstated federal research tax credit, partially offset by a slight increase in expected operating expenses. 
  • Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute acquisitions or dispositions in fiscal 2013 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory co
    '/>"/>

    SOURCE Hologic, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
    2. Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 2012
    3. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
    4. Hologic, Inc. Announces Note Offering
    5. Hologic And Gen-Probe Provide Update On Pending Transaction
    6. Hologic and Gen-Probe Announce Clearance from German Federal Cartel Office for Hologics Acquisition of Gen-Probe
    7. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
    8. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
    9. Hologic Announces Third Quarter Fiscal 2012 Operating Results
    10. Hologic Completes Acquisition Of Gen-Probe
    11. Senator Blumenthal, a Strong Advocate for Womens Health, Visits Hologics Manufacturing Facility in Danbury, CT
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... Texas , May 28, 2015   Lexicon ... that Lexicon management will present at the Jefferies 2015 ... a.m. Eastern Time in New York ... clinical development programs and milestones. A webcast ... at www.lexpharma.com . An archived version of the ...
    (Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
    (Date:5/28/2015)... MONICA, Calif. , May 28, 2015 ... doctors to check a state prescription database before prescribing ... addiction and thousands of overdose deaths. SB ... Bell Gardens , will require prescribers to ... (CURES) before prescribing Schedule II and III drugs, like ...
    Breaking Medicine Technology:Lexicon To Present At The Jefferies 2015 Healthcare Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2
    ... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
    ... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
    Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
    (Date:5/28/2015)... Recently, KORT Richmond, 5006 Atwood Drive, added a ... of life. The program works with those new to prosthetic ... but are still having difficulty. , According to the ... with limb loss in the United States. The main causes ... peripheral arterial disease – trauma (45%) and cancer (less than ...
    (Date:5/28/2015)... Bronx, NY (PRWEB) May 28, 2015 ... Urgent Care are proud to present Dr. Alicia Almendral ... will be a big part of the newly opened ... very finest in modern cosmetic treatments. , Dr. Almendral ... experienced in the latest anti-aging and cosmetic enhancement techniques. ...
    (Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
    (Date:5/28/2015)... 28, 2015 Dr. Jenyons’ Medical ... exclusive deal to patients looking to undergo its advanced ... 30, patients will be able to get a single ... just $600. For a three-treatment package, which costs $1,800, ... no cost. , Dr. Juanita Jenyons, M.D., says Dr. ...
    (Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
    Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
    ... Not enough Scottish children are receiving MMR shots, say ... 92.1 per cent of two-year-olds were given the jab, which protects ... 95 per cent. , Yet, this is an ... cent. ,MMR vaccines were introduced in 1988, but ...
    ... medicine of Sanofi-Aventis will be made indigenously in Thailand. This ... ,As per the offer made by Sanofa-Aventis, the health ministry ... the drug. The statement released by the drug firm states ... poorer Thai patients. According to a health official the company ...
    ... rice bran could reduce the risk of intestinal cancer.// ... Department of Cancer Studies and Molecular Medicine, University of Leicester. ... in the laboratory has produced promising results. ... Cancer. ,The results of a controlled laboratory ...
    ... cancer patients unable to undergo surgery have another safe ... a new study. ,The Brown Medical ... ablation used to treat early-stage, inoperable cancer resulted in ... achieved through external beam radiation (EBT), a decades-old alternative ...
    ... Scientists have created the world's first human-sheep chimera - which ... ,The sheep have 15 per cent human cells ... brings the prospect of animal organs being transplanted into humans ... the University of Nevada, has spent seven years and ?5 ...
    ... Rift Valley Fever (RVF) among animals began on 18 ... the beginning// of February 2007 in Arusha region. A ... Country Office, WHO Regional Office for Africa, Centers for ... including active case finding and specimen collection. Two cases ...
    Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:RF Ablation a Safe Alternative Option for Treating Lung Cancer 2Health News:Now Scientists Create a Sheep That's 15% Human 2Health News:Rift Valley Fever in the United Republic of Tanzania 2
    Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
    Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
    Used for the introduction of catheters, balloons and other vascular devices....
    Used to introduce large devices for vascular intervention....
    Medicine Products: